Ben Pope | BiotechTV

top of page

Align Summit 2026: Natick based MelliCell is targeting MNK (MAPK-interacting kinase), a genetic switch that could make a difference in fragile X syndrome and beyond

Founder Ben Pope describes the rationale of hitting the target and why he believes a clinical trial in Fragile X could provide evidence of the target's relevance in obesity, Alzheimer's, and more. Coverage brought to you by

Company News

3 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

Align Summit 2026: Natick based MelliCell is targeting MNK (MAPK-interacting kinase), a genetic switch that could make a difference in fragile X syndrome and beyond

Follow BiotechTV

Sponsors

Sponsor Spotlight